Pharmacodynamic profile of CQP 201-403, a novel 8 alpha-amino-ergoline.
The profile of action in animals of CQP 201-403, a novel 8 alpha-amino-ergoline, is in most aspects that of a very potent dopaminomimetic, both as a prolactin secretion inhibitor, and at the levels of the CNS and the cardiovascular system. Qualitatively CQP 201-403 differs slightly from bromocriptine and apomorphine in its effects on the CNS (no influence on serotonin metabolism in the rat cortex; induction of masculine mounting behavior in rats) and the cardiovascular system of the dog (reflex tachycardia in response to a blood-pressure fall). In man the new compound proved to be highly active in lowering prolactin serum levels and be more potent than bromocriptine (Parlodel).
Flückiger
E
E
Preclinical Research, Pharma, Sandoz Ltd., Basel, Switzerland.
Briner
U
U
Clark
B
B
Closse
A
A
Enz
A
A
Gull
P
P
Hofmann
A
A
Markstein
R
R
Tolcsvai
L
L
Wagner
H R
HR
D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D001667:Binding, Competitive; D001921:Brain / Q000378:metabolism; D002462:Cell Membrane / Q000378:metabolism; D004285:Dogs; D004298:Dopamine / Q000378:metabolism; D010064:Embryo Implantation / Q000187:drug effects; D004873:Ergolines / Q000378:metabolism / Q000494:pharmacology*; D005260:Female; D006439:Hemodynamics / Q000187:drug effects; D007774:Lactation / Q000187:drug effects; D008297:Male; D051379:Mice; D008893:Milk Ejection / Q000187:drug effects; D009043:Motor Activity / Q000187:drug effects; D009638:Norepinephrine / Q000378:metabolism; D011247:Pregnancy; D011388:Prolactin / Q000097:blood; D051381:Rats; D011919:Rats, Inbred Strains; D012701:Serotonin / Q000378:metabolism
D004873:Ergolines; C049850:CQP 201-403; D012701:Serotonin; D011388:Prolactin; D004298:Dopamine; D009638:Norepinephrine